Clinical proteomics in lung diseases

被引:16
|
作者
Waldburg, N
Kähne, T
Reisenauer, A
Röcken, C
Welte, T
Bühling, F
机构
[1] Univ Magdeburg, Inst Immunol, D-39120 Magdeburg, Germany
[2] Univ Magdeburg, Div Pneumol & Crit Care, D-39120 Magdeburg, Germany
[3] Univ Magdeburg, Inst Expt Internal Med, D-39120 Magdeburg, Germany
[4] Univ Magdeburg, Inst Pathol, D-39120 Magdeburg, Germany
关键词
lung; proteomics; disease;
D O I
10.1016/j.prp.2004.02.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Proteomics is a relatively new approach for understanding the pathology and pathogenesis of various diseases. It has also been used for characterizing the modifications in protein expression during the development of interstitial lung diseases, in lung tumors, or following exposure to exogenous stress signals. We compared the protein composition of primary human lung fibroblasts derived from patients with lung fibrosis and control fibroblasts of unaffected lung tissues. We found a predominant modulation in proteins related to the cytoskeleton, including decreased expression of vimentin and lamin A/C, and increased expression of moesin. Furthermore, we observed lower levels of components of the antioxidative system, such as omega class glutathione S-transferase and an up-regulation of an intracellular chloride channel. In fibroblasts obtained from fibrotic lungs, the expression of a major histocompatibility complex class 1 C was decreased, and so was the expression of tripeptidyl-peptidase-I-precursor, a collagen-degrading exopeptidase. Our results and the studies reviewed in this paper represent just the beginning of detailed studies that should unravel the relevance and the functional consequences of differential protein expressions in the diseased lung. (C) 2004 Elsevier GmbH. All rights reserved.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 50 条
  • [1] Editorial: Clinical application of proteomics in kidney diseases
    Pejchinovski, Martin
    Magalhaes, Pedro
    Metzeger, Jochen
    FRONTIERS IN MEDICINE, 2022, 9
  • [2] Proteomics: Clinical and research applications in respiratory diseases
    Norman, Katy C.
    Moore, Bethany B.
    Arnold, Kelly B.
    O'Dwyer, David N.
    RESPIROLOGY, 2018, 23 (11) : 993 - 1003
  • [3] Lung cancer proteomics, clinical and technological considerations
    Lehtio, Janne
    De Petris, Luigi
    JOURNAL OF PROTEOMICS, 2010, 73 (10) : 1851 - 1863
  • [4] Proteomics in detection and monitoring of asthma and smoking-related lung diseases
    Lin, Jiun-Lih
    Bonnichsen, Mark H.
    Nogeh, Emily U.
    Raftery, Mark J.
    Thomas, Paul S.
    EXPERT REVIEW OF PROTEOMICS, 2010, 7 (03) : 361 - 372
  • [5] Biomarker discovery in lung cancer - Promises and challenges of clinical proteomics
    Bharti, Ajit
    Ma, Patrick C.
    Salgia, Ravi
    MASS SPECTROMETRY REVIEWS, 2007, 26 (03) : 451 - 466
  • [6] Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases
    Huang, Chun-Hao
    Chiou, Shyh-Horng
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (06) : 1529 - 1536
  • [7] Clinical proteomics identifies potential biomarkers in Helicobacter pylori for gastrointestinal diseases
    Chun-Hao Huang
    Shyh-Horng Chiou
    World Journal of Gastroenterology, 2014, 20 (06) : 1529 - 1536
  • [8] Clinical proteomics: The application of proteomics in the research of clinical medicine
    Li, F
    Fang, Y
    Xiao, ZQ
    Chen, ZC
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2006, 33 (01) : 5 - 9
  • [9] The proteomics of lung injury in childhood: challenges and opportunities
    Pereira-Fantini, Prue M.
    Tingay, David G.
    CLINICAL PROTEOMICS, 2016, 13
  • [10] Proteomics of lung physiopathology
    Miller, Ingrid
    Eberini, Ivano
    Gianazza, Elisabetta
    PROTEOMICS, 2008, 8 (23-24) : 5053 - 5073